The Vermont Prescription Drug Discount Card Program (H.577) - Overview & Analysis

The Vermont Prescription Drug Discount Card Program (H.577) - Overview & Analysis

H.577 would create a statewide Vermont Prescription Drug Discount Card Program, administered by the State Treasurer, to pool Vermont’s prescription drug purchasing power with other states. The goal is to negotiate lower prices on medications for all Vermonters. The bill sets up the legal authority for joining multi-state purchasing/discount arrangements, allows modest fees to sustain the program, establishes a dedicated fund, and provides start-up money and reporting requirements so lawmakers can monitor implementation, costs, and savings over time.

The Details:

  • Vermont Prescription Drug Discount Card Program
    • Establishes the Vermont Prescription Drug Discount Card Program and places it under the administration of the Office of the State Treasurer.
    • States the core purpose: to pool Vermont’s prescription drug purchasing power with other U.S. states, territories, and nongovernmental organizations to obtain better prices.
    • Makes the program available to all Vermont residents (universal eligibility, not income- or age-limited).
    • Allows the Treasurer to charge reasonable fees to defray program costs and gives the Treasurer discretion to set the amount and collection method based on actual costs, notwithstanding other fee-setting statutes.
    • Requires an annual report (by Jan. 15, 2028, and each year thereafter).
  • Vermont Prescription Drug Discount Card Program Fund
    • Creates a special fund—the Vermont Prescription Drug Discount Card Program Fund—administered by the State Treasurer.
    • Specifies potential sources of funding as:
      • Legislative appropriations
      • Transfers from federal government, other State agencies, or other governmental sources
      • Fees or other monies paid to the Program
      • Gifts, grants, donations, and investment income related to the Program.
      • Requires interest and investment income to be credited back to the Fund.
      • States that unexpended balances do not revert at year-end; they remain in the Fund for future use.
  • Implementation report

    • Directs the State Treasurer to report to the General Assembly on progress in implementing the Program as of January 15, 2027.

    • Report must include:
      • Recommendations to improve administration
      • Proposed participant fees (if any)
      • An estimate of projected State costs if additional financial support is needed to administer the Program beyond fees and existing resources.
  • Evaluation and start-up funding

    • Appropriates $50,000 from the General Fund in FY2027 to the Office of the State Treasurer.

    • Funds are for developing and implementing the Vermont Prescription Drug Discount Card Program (planning, contracting, outreach, systems, etc.).

  • Effective date
    • The act takes effect July 1, 2026.

The Good:

  • Lower out-of-pocket costs for residents 
    By joining a multi-state discount arrangement such as ArrayRx, Vermonters could get a free discount card with significant savings—program partners report up to ~80% off generics and ~20% off brand-name drugs at the pharmacy counter.

  • Universal eligibility and simple access
    The bill covers all Vermont residents, regardless of insurance status or income, which helps underinsured and those hit by loss of ACA subsidies or high deductibles.

  • Limited fiscal risk to the State 
    The program is primarily financed via negotiated discounts with manufacturers and pharmacies; Vermont’s direct budget exposure in the bill is modest ($50k start-up + any later support, subject to legislative oversight).

  • Aligns with broader efforts to combat nonadherence due to cost (public health)
    About one in three U.S. adults on prescriptions report not taking medications as prescribed because of cost; additional discounts could reduce dangerous skipping or rationing of medications

The Bad:

  • Savings may be uneven or modest for some drugs 
    Discount cards often deliver strong savings on many generics but limited help for certain high-cost specialty drugs; expectations may exceed actual relief for the sickest patients.

  • Complexity and potential confusion 
    Residents must understand when to use the discount card vs. their insurance or Medicare—if the discount is better than the insured price. This can be confusing at the counter and requires clear education.

  • Discount cards operate outside full insurance protections 
    Purchases via discount cards typically don’t count toward insurance deductibles or out-of-pocket maximums; frequent use could leave people financially exposed, even as they pay less per fill.

  • Not a structural fix to drug pricing
    The bill helps Vermonters cope with prices at the point of sale but does not directly regulate manufacturers’ list prices, patent practices, or broader system incentives.

  • Pharmacy margin concerns 
    While Vermont officials indicate ArrayRx’s model is designed so pharmacies are not undercut, pharmacies often worry that discount arrangements can squeeze margins and shift administrative workload. wcx

Analysis:

Taken together, H.577 appears to be a low-cost, low-risk, and potentially high-yield measure to improve prescription drug affordability for Vermonters:

  • It leverages proven models in other states and existing multi-state infrastructures like ArrayRx.
  • It offers universal access, with particular benefit for underinsured and middle-income residents squeezed by high deductibles and rising premiums.
  • It includes reporting and a dedicated fund, giving the Legislature tools to monitor outcomes and adjust the program.

Its main limitations are that it does not tackle drug prices at their root and may provide less relief for very high-cost specialty drugs. But as a pragmatic, near-term affordability tool that complements deeper structural reforms, it represents a positive and sensible development, especially if coupled with strong transparency, oversight of contracting, and a willingness to iterate based on the required annual reports.

 

Current Status:

The bill has been introduced in the House and is being reviewed by the House Health Care Committee.

 

Last updated: 1/17/2026

DISCLAIMER: Generative AI used to assist in the production of this report.

News coverage on H.577

Read the Bill

More bill summaries

 

Recent responses